MIMS Monthly Up­date

Pharmacy Daily - - NEWS -

New Prod­ucts

An­ti­zol (fomepi­zole) is a com­pet­i­tive in­hibitor of al­co­hol de­hy­dro­ge­nase. Al­co­hol de­hy­dro­ge­nase catal­y­ses the ox­i­da­tion of ethanol to ac­etalde­hyde. Al­co­hol de­hy­dro­ge­nase also catal­y­ses the ini­tial steps in the me­tab­o­lism of eth­yl­ene gly­col and methanol to their toxic me­tab­o­lites. Meta­bolic aci­do­sis and re­nal dam­age are seen with eth­yl­ene gly­col tox­i­co­sis. Meta­bolic aci­do­sis and vis­ual dis­tur­bances (e.g. de­creased vis­ual ac­tiv­ity and po­ten­tial blind­ness) are as­so­ci­ated with methanol poi­son­ing. An­ti­zol is in­di­cated for the treat­ment of eth­yl­ene gly­col or methanol poi­son­ing. An­ti­zol so­lu­tion for in­tra­venous in­fu­sion (fomepi­zole 1.5 g/1.5 mL) is sup­plied in a pack of 4 vials.

New In­di­ca­tions

Frax­i­parine (nadroparin cal­cium) is now in­di­cated for pro­phy­laxis of ve­nous throm­boem­bolism in high-risk med­i­cal pa­tients who are im­mo­bilised due to acute ill­ness or hos­pi­talised in an in­ten­sive care unit.

Keytruda (pem­brolizumab (rch)) as monother­apy is now in­di­cated for the treat­ment of adults with re­lapsed or re­frac­tory clas­si­cal Hodgkin lym­phoma fol­low­ing au­tol­o­gous stem cell trans­plant (ASCT), or fol­low­ing at least two prior ther­a­pies when ASCT or multi-agent chemo­ther­apy is not a treat­ment op­tion. The ap­proval of this in­di­ca­tion is on the ba­sis of ob­jec­tive re­sponse rate.

New Con­traindi­ca­tions

In­vi­rase (saquinavir) is now con­traindi­cated with con­comi­tant rilpivirine, dasa­tinib or suni­tinib due to po­ten­tially life threat­en­ing car­diac ar­rhyth­mia, or lurasi­done due to po­ten­tially se­ri­ous and/or life threat­en­ing re­ac­tions.

Mer­syn­dol and Panal­gesic (parac­eta­mol, codeine phos­phate hemi­hy­drate and doxy­lamine suc­ci­nate) are now con­traindi­cated in chil­dren younger than 12 years.

Mer­syn­dol Day Strength, Pana­max Co, Prodeine and Prodeinex­tra (parac­eta­mol, codeine phos­phate hemi­hy­drate) are now con­traindi­cated in chil­dren younger than 12 years.

Navel­bine (vi­norel­bine tar­trate) is now con­traindi­cated with neu­trophil count < 1500 cells/mm3, cur­rent or re­cent in­fec­tion (within 2 weeks), platelet count < 100,000 cells/mm3, or use in com­bi­na­tion with yel­low fever vac­cine.

Neu­lac­til (peri­ci­azine) is now con­traindi­cated with pre­vi­ous his­tory of agran­u­lo­cy­to­sis, risk of uri­nary re­ten­tion due to ure­thro­pro­static dis­or­ders, chil­dren younger than 1 year (due to a pos­si­ble link be­tween use of phe­noth­iazine con­tain­ing prod­ucts and sud­den in­fant death syn­drome), or in com­bi­na­tion with dopamin­er­gic an­tiparkin­son­ism agents.

Proc­tosedyl (cin­chocaine hy­drochlo­ride, hy­dro­cor­ti­sone) is now con­traindi­cated in bac­te­rial, fungal or par­a­sitic in­fec­tions.

Zo­mac­ton (so­ma­t­ropin (rbe)) treat­ment should be dis­con­tin­ued at re­nal trans­plan­ta­tion in chil­dren with chronic re­nal dis­ease. This list is a sum­mary of only some of the changes that have oc­curred over the last month. Be­fore pre­scrib­ing, al­ways re­fer to the full prod­uct in­for­ma­tion.

Newspapers in English

Newspapers from Australia

© PressReader. All rights reserved.